Forbes August 15, 2022
Robert Hart

Topline

The U.K. has authorized Moderna’s Covid vaccine that targets two different variants of the virus, the nation’s medicines regulator announced on Monday, a world first as pharma firms adapt to a changed viral landscape and countries prepare to launch fall booster campaigns.

Key Facts

Key Background

The virus circulating today has shifted significantly from the original one identified back in 2020. Vaccines, meanwhile, are still based on the original variant and while they still provide strong protection against serious illness, hospitalization and death, experts fear this could change with future variants. Most major Covid vaccine makers—including Pfizer, Moderna, Johnson & Johnson and Novavax—have been working on shots specific to the omicron variant to address waning effectiveness against the variant...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article